WallStreetZenWallStreetZen

NASDAQ: CRDL
Cardiol Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

CRDL past revenue growth

How has CRDL's revenue growth performed historically?
Company
-100%
Industry
6.48%
Market
14.01%
CRDL's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CRDL's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

CRDL earnings and revenue history

Current Revenue
$0.0
Current Earnings
-$21.1M
Current Profit Margin
0%

CRDL Return on Equity

Current Company
-53%
Current Industry
15.5%
Current Market
34.8%
CRDL's Return on Equity (-53%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when CRDL announces earnings.

CRDL Return on Assets

Current Company
-45.2%
Current Industry
5.6%
CRDL is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CRDL Return on Capital Employed

Current Company
-63.79%
Current Industry
10.3%

CRDL vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CRDL$0.00-$21.21M-$21.37M-100.00%N/A
HEXO$107.31M-$240.76M-$226.02M+60.62%N/A
TXMD$51.05M$143.17M$157.42M+25.24%N/A
HUGE$0.00-$16.96M-$20.34MN/AN/A
COSM$49.63M-$10.31M-$58.82M+5.56%N/A
View Top Pharmaceutical Stocks

Cardiol Therapeutics Earnings & Revenue FAQ

What were CRDL's earnings last quarter?

On Invalid Date, Cardiol Therapeutics (NASDAQ: CRDL) reported Q1 2023 earnings per share (EPS) of -$0.08, up 27.93% year over year. Total Cardiol Therapeutics earnings for the quarter were -$5.14 million. In the same quarter last year, Cardiol Therapeutics's earnings per share (EPS) was -$0.11.

If you're new to stock investing, here's how to buy Cardiol Therapeutics stock.

What was CRDL's earnings growth in the past year?

As of Q2 2023, Cardiol Therapeutics's earnings has grown year over year. Cardiol Therapeutics's earnings in the past year totalled -$21.37 million.

What was CRDL's revenue last quarter?

On Invalid Date, Cardiol Therapeutics (NASDAQ: CRDL) reported Q1 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Cardiol Therapeutics's revenue was $0.00.

What was CRDL's revenue growth in the past year?

As of Q2 2023, Cardiol Therapeutics's revenue has grown -100% year over year. This is 106.48 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 6.48%. Cardiol Therapeutics's revenue in the past year totalled $0.00.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.